PV 701 - Wellstat Biologics

Drug Profile

PV 701 - Wellstat Biologics

Alternative Names: PV701

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wellstat Biologics Corporation
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cervical cancer; Colorectal cancer

Most Recent Events

  • 18 Sep 2006 Phase-II clinical trials in Cervical cancer in USA (IV)
  • 18 Sep 2006 Phase-II clinical trials in Colorectal cancer in USA (IV)
  • 03 Mar 2003 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top